Vancomycin use in a Brazilian teaching hospital: Comparison with the Hospital Infection Control Practices Advisory Committee Guidelines (HICPAC)

Brazilian Journal of Infectious Diseases

Volumn 13, Issue 3, 2009, Pages 161-164

  De Melo, Daniela Oliveira ^a   Ribeiro, Eliane ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antimicrobial use; Guidelines; Infection; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; BRAZIL; CATHETER INFECTION; CHILD; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG USE; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HOSPITAL ORGANIZATION; HUMAN; INFECTION CONTROL; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT MONITORING; PERITONITIS; PRACTICE GUIDELINE; PRESCRIPTION; RISK FACTOR; SEPSIS; SEPTICEMIA; TEACHING HOSPITAL; TREATMENT INDICATION; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BRAZIL; DRUG UTILIZATION; GUIDELINE ADHERENCE; HOSPITALS, UNIVERSITY; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; VANCOMYCIN;

EID: 77749283203     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702009000300001     Document Type: Article

References (43)

1. Edmond M.B., Wallace S.E., McClish D.K. et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44.
2. Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P. Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000; 21:510-15.
3. Solomkin J.S., Bjornson H.S., Cainzos M. et al. A consensus statement on empiric therapy for suspected Gram-positive infections. The Am J of Surg 2004;187:134-145.
4. Cieslak P.R., Strausbaugh L.J., Fleming D.W., Ling J.M. Vancomycin in Oregon: who's using it and why. Infect Control Hosp Epidemiol 1999;20(8):557-560.
5. Centers of Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance - Recommendations Infection Control Practices Advisory Committee (HICPAC). MMWR 1995; 44(RR12): 1-13.
6. Noble W.C., Virani Z., Cree R. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC12201 to Staphylococcus aureus. Microbiol Lett 1992;72:195-8.
7. Smith T.L., Pearson M.L., Wilcox K.R. et al. emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus working Group. N Engl J Med 1999;340:493- 501.
8. Thomas R.A., Cieslak R.P., Straugsbaugh J.L., Fleming W.D. Effectiveness of pharmacy policies designed to limit inappropriate vancomycin use: A population- based assessment. Infect Control Hosp Epidemiol 2002;23:683- 8.
9. Hiramatsu K., Hanaki H., Ino T. et al. Methicillin-resistant Staphylococcus aureus clinical strengh with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.
10. Rotun S.S., McMath V., Schoonmaker D. et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999;5:147-9.
11. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibily to vancomycin: Illinois, 1999. MMWR 2000;48:1165-7.
12. Centers for Disease Control and Prevention. Public Health dispatch: Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR 2002;51(40):902-3.
13. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR 2002;51:565-7.
14. Camargo I.L., Zanella R.C., Brandileone M.C. et al. Occurrence of insertion sequences within the genomes and Tn 1546-like elements of glycopeptide-resistant enterococci isolated in Brazil, and identification of a novel element, ISEfa5. Int J Med Microbiol 2005;294(8):513-9.
15. Palazzo I.C., Araujo M.L., Darini A.L. First report of vancomycin-resistant staphylococci isolated from healthy carriers in Brazil. J Clin Microbiol 2005;43(1):179-85.
16. Kluytmans-Vandenbergh M.F., Kluytmans J.A. Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin Microbiol Infect 2006;12 Suppl 1:9-15.
17. Schaberg D.R., Culver D.H., Gaynes R.P. Major trends in microbial etiology of nosocomial infection. Am J Med 1991;919(suppl 3B):72S-5S.
18. Lautenbach E., Biulker W.B., Brennan P.J. Enterococcal bacterimia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol 1999;20:318-23.
19. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report: data summary from October 1986-April 1998, issued June 1998. Am J Infect Control 1998;26:522-33.
20. Hachem R., Graviss L., Hanna H. et al. Impact of surveillance for vancomycin-resistant enterococci on controlling a bloodstream outbreak among patients with hematologic malignancy. Infect Control Hosp Epidemiol 2004;25:391-4.
21. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United Sates, 1989-1993. MMWR 1993;42:597-9.
22. Grayson M.L., Grabsch E.A., Johnson P.D. et al. Outcome of a screening program for vancomycin-resistant enterococci in a hospital in Victoria. Med J Aust 1999;171:133-6.
23. Hendrix C.W., Hammond J.M.J., Swoboda S.M. et al. Surveillance strategies and impact of vancomycin-resistant enterococcal colonization and infection in critically ill patients. Ann Surg 2001;233:259-65.
24. Price C.S., Paule S., Noskin G.A., Peterson L.R. Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 2003;37:921-8.
25. Montecalvo M.A., Jarvis W.R., Uman J. et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999;131:269-72.
26. Ostrowsky B.E., Trick W.E., Sohn A.H. et al. Control of vancomycin-resistant Enterococcus in health care facilities in a region. N Engl J Med 2001;344:1427-33.
27. Morgan S.A., Brennan J.P., Fishman O.N. Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus. Ann Pharmacother 1997;31:1,970- 3.
28. National Nosocomial Infections Surveillance (NNIS) System. National Nosocomial Infections Surveillance System report: data summary from January 1992-June 2001. Am J Infect Control 2001;29:404-21.
29. Christiansen K.J., Tibbett P.A., Beresfor W. et al. Eradication of a large outbreak of a single strain of van B vancomycin-resistant Enterococcus faecium at a major Australian teaching hospital. Infect Control Hosp Epidemiol 2004;25:384-90.
30. Zanella R.C., Valdetaro F., Lovgren M. et al. First confirmed case of a vancomycin-resistant Enterococcus faecium with vanA phenotype from Brazil: isolation from a meningitis case in Sao Paulo. Microb Drug Resist 1999;5(2):159-62.
31. Cereda R.F., Gales A.C., Silbert S. et al. Molecular typing and antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium in Brazil. Infect Control Hosp. Epidemiol 2002;23(1):19-22.
32. Edmond M.B., Ober J.F., Dawson J.D. et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:1234-9.
33. Lodise T.P., Mckinnon P.S., Tam V.H., Rybak M.J. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis 2002;34:922-9.
34. Carmeli Y., Eliopoulos G., Mozaffari E., Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002;162:2223-8.
35. Schumacher G.E. Therapeutic drug monitoring. Connecticut: Appleton & Lange; 1995.
36. Melo D.O., Sasaki M., Grinbaum R.S. Vancomycin use in a Hospital with High Prevalence of Methicillin-Resistant Staphylococcus aureus: Comparison with Hospital Infection Control Practices Advisory Committee Guidelines (HICPAC). Braz J Infect Dis 2007;11(1):53-7.
37. Evans M.E., Kortas K.J. Vancomycin use in a university medical center: comparison with Hospital Infection Control Practices Advisory Committee Guidelines. Infect Control Hosp Epidemiol 1996;17:356-9.
38. Rehm S.J. Two new treatment options for infections due to drug-resistant Gram-positive cocci. Cleve Clin Med 2002; 69:397-413.
39. Singer M.V., Haft R., Barlan T., et al. Vancomycin control measures at a tertiary-care hospital: impact of interventions on volume and patterns of use. Infect Control Hosp Epidemiol 1998;19:248-53.
40. Montravers P., Gauzit R., Muller C., et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996;23:486-94.
41. Van Houten N.A., Uiterwaal C.S.P.M., Heesen G.J.M. et al. Does the empiric use of vancomycin in pediatrics increase the risk for Gram-negative bacteremia? Pediatr Infect Dis J 2001;20:171-7.
42. Watanakunakorn, C. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of vancomycin resistant enterococci. Infect Control Hosp Epidemiol 1997;18:767-9.
43. Fridkin S.K., Steward C.D., Edwards J.R. et al. Surveillance of antimicrobial use in United States hospitals: project ICARE phase 2. Clin Infect Dis 1999;29:245-52.